

# Uri Kopylov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5820324/publications.pdf>

Version: 2024-02-01

262  
papers

12,195  
citations

31902

53  
h-index

30010

103  
g-index

266  
all docs

266  
docs citations

266  
times ranked

8408  
citing authors

#	ARTICLE	IF	CITATIONS
1	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 144-164K.	0.6	958
2	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 769-784.	0.6	876
3	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
4	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
5	Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1444-1449.e1.	2.4	325
6	Optimizing anti-TNF treatments in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 24-30.	2.5	322
7	Optimizing Anti-TNF Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 550-557.e2.	2.4	312
8	Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 444-447.	2.4	291
9	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
10	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 522-530.e2.	2.4	268
11	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. <i>Gut</i> , 2014, 63, 1258-1264.	6.1	266
12	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 273-284.	0.6	250
13	The immunogenic part of infliximab is the F(ab') <sub>2</sub> , but measuring antibodies to the intact infliximab molecule is more clinically useful. <i>Gut</i> , 2011, 60, 41-48.	6.1	195
14	Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1427-1434.e2.	2.4	187
15	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 879-913.	0.6	177
16	Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 620-628.	1.9	162
17	Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2404-2413.	0.9	154
18	Deep learning algorithms for automated detection of Crohn's disease ulcers by video capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 606-613.e2.	0.5	149

#	ARTICLE	IF	CITATIONS
19	Clinical Utility of Fecal Biomarkers for the Diagnosis and Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 742-756.	0.9	138
20	Deep learning for wireless capsule endoscopy: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 831-839.e8.	0.5	138
21	Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's diseaseâ€”The McGill experience. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1516-1522.	0.6	132
22	Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. <i>American Journal of Gastroenterology</i> , 2015, 110, 1316-1323.	0.2	125
23	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
24	Vedolizumab in IBDâ€”Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 245-257.	0.6	119
25	Association of Vedolizumab Level, Anti-Drug Antibodies, and Î±4Î²7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 697-705.e7.	2.4	103
26	Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 555-558.	0.6	101
27	Small Bowel Capsule Endoscopy in the Management of Established Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 93-100.	0.9	101
28	Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn's disease: Systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2017, 49, 854-863.	0.4	101
29	Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 276-282.	1.9	98
30	KID Project: an internet-based digital video atlas of capsule endoscopy for research purposes. <i>Endoscopy International Open</i> , 2017, 05, E477-E483.	0.9	92
31	Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1137-1144.	0.8	87
32	Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw182.	0.6	85
33	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Diseaseâ€”the Israeli Real-World Experience. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 404-408.	0.9	84
34	Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1632-1641.	0.6	83
35	The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 349-357.	1.9	82
36	Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1628-1633.	0.9	78

#	ARTICLE	IF	CITATIONS
37	Vitamin B12 Deficiency in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	0.9	78
38	Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1847-1853.	0.9	77
39	The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 49-59.	3.7	76
40	Undetectable anti- $\alpha$ -TNF drug levels in patients with long-term remission predict successful drug withdrawal. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 356-364.	1.9	74
41	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , 2011, 60, 456-462.	6.1	72
42	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1293-1299.	1.9	72
43	Obesity, Metabolic Syndrome and the Risk of Development of Colonic Diverticulosis. <i>Digestion</i> , 2012, 86, 201-205.	1.2	71
44	Use of patency capsule in patients with established Crohn's disease. <i>Endoscopy</i> , 2016, 48, 373-379.	1.0	69
45	Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 890-898.	0.2	67
46	Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 513-526.	1.4	64
47	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 525-531.	0.6	64
48	Clinical outcomes of negative small-bowel capsule endoscopy for small-bowel bleeding: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 305-317.e2.	0.5	64
49	Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 212-218.	1.9	63
50	Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 519-528.	3.7	63
51	Vedolizumab and Anti-Tumour Necrosis Factor $\pm$ Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1694-1706.	0.6	62
52	Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence. <i>Digestive and Liver Disease</i> , 2019, 51, 1232-1240.	0.4	59
53	Prediction of patency capsule retention in known Crohn's disease patients by using magnetic resonance imaging. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 182-187.	0.5	57
54	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2442-2451.	0.9	56

#	ARTICLE	IF	CITATIONS
55	Ulcer severity grading in video capsule images of patients with Crohn's disease: an ordinal neural network solution. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 187-192.	0.5	56
56	The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 714-722.	1.9	53
57	Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 135-142.	1.9	51
58	Capsule Endoscopy, Magnetic Resonance Enterography, and Small Bowel Ultrasound for Evaluation of Postoperative Recurrence in Crohn's Disease: Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 93-100.	0.9	50
59	Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2327-2338.	0.9	50
60	Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease Flares. <i>American Journal of Gastroenterology</i> , 2019, 114, 1142-1151.	0.2	50
61	Magnetic resonance enterography in Crohn's disease: A guide to common imaging manifestations for the IBD physician. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 603-615.	0.6	48
62	Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 369-378.	0.6	48
63	Perception of Reproductive Health in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 886-891.	0.6	46
64	Role of capsule endoscopy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1155.	1.4	45
65	Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1663-1676.	1.0	44
66	Automated Detection of Crohn's Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 749-756.	0.6	43
67	Advances in the development of new biologics in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2016, 29, 243-8.	0.4	41
68	Magnetic resonance enterography <i>versus</i> capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 655-663.	1.4	41
69	Clinical validity of flexible spectral imaging color enhancement (FICE) in small-bowel capsule endoscopy: a systematic review and meta-analysis. <i>Endoscopy</i> , 2017, 49, 258-269.	1.0	41
70	Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878557.	1.4	41
71	Nomenclature and semantic description of vascular lesions in small bowel capsule endoscopy: an international Delphi consensus statement. <i>Endoscopy International Open</i> , 2019, 07, E372-E379.	0.9	40
72	Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 145-150.	1.9	39

#	ARTICLE	IF	CITATIONS
73	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	2.4	39
74	Antiviral therapy in cytomegalovirus-positive ulcerative colitis: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 2695.	1.4	39
75	The Lewis score or the capsule endoscopy Crohn's disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn's disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774778.	1.4	38
76	A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481876595.	1.4	38
77	Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNF $\pm$ Antagonists. <i>Frontiers in Immunology</i> , 2019, 10, 2921.	2.2	38
78	A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 544-551.	1.6	38
79	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 135-139.	0.4	37
80	Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2982-2990.	1.1	36
81	Detection of Crohn Disease in Patients with Spondyloarthritis: The SpACE Capsule Study. <i>Journal of Rheumatology</i> , 2018, 45, 498-505.	1.0	36
82	Capsule endoscopy in young patients with iron deficiency anaemia and negative bidirectional gastrointestinal endoscopy. <i>United European Gastroenterology Journal</i> , 2017, 5, 974-981.	1.6	35
83	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1076-1085.	1.6	35
84	Clinical Outcomes of Surgery Versus Endoscopic Balloon Dilation for Stricturing Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 1151-1157.	0.7	34
85	Symptomatic retention of the patency capsule: a multicenter real life case series. <i>Endoscopy International Open</i> , 2016, 04, E964-E969.	0.9	34
86	Nomenclature and semantic descriptions of ulcerative and inflammatory lesions seen in Crohn's disease in small bowel capsule endoscopy: An international Delphi consensus statement. <i>United European Gastroenterology Journal</i> , 2020, 8, 99-107.	1.6	34
87	Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1488-1493.	0.6	34
88	Reciprocal regulation of CXCR4 and CXCR7 in intestinal mucosal homeostasis and inflammatory bowel disease. <i>Journal of Leukocyte Biology</i> , 2011, 90, 583-590.	1.5	33
89	Therapeutic drug monitoring in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2014, 27, 304-312.	0.4	33
90	Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 248-255.	1.6	32

#	ARTICLE	IF	CITATIONS
91	Prognosis of Primary Sclerosing Cholangitis in Israel is Independent of Coexisting Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 177-184.	0.6	30
92	Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 686-692.	0.6	29
93	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	1.0	29
94	Severe and Morbid Obesity in Crohn's Disease Patients: Prevalence and Disease Associations. <i>Digestion</i> , 2013, 88, 26-32.	1.2	28
95	A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. <i>Patient</i> , 2020, 13, 317-325.	1.1	28
96	Clinical applications of small bowel capsule endoscopy. <i>Clinical and Experimental Gastroenterology</i> , 2013, 6, 129.	1.0	27
97	Magnetic resonance enterography in pregnant women with Crohn's disease: case series and literature review. <i>BMC Gastroenterology</i> , 2014, 14, 146.	0.8	27
98	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus: A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1605-1613.	0.9	27
99	Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 491-498.	0.7	26
100	Video Capsule Endoscopy of the Small Bowel for Monitoring of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2726-2735.	0.9	26
101	Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy: A Multicenter Retrospective Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2033-2040.	1.1	26
102	Magnetic resonance enterography or video capsule endoscopy &ndash; what do Crohn's disease patients prefer?. <i>Patient Preference and Adherence</i> , 2016, 10, 1043.	0.8	24
103	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	1.9	24
104	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease: The Israeli real world experience. <i>Digestive and Liver Disease</i> , 2019, 51, 68-74.	0.4	24
105	Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. <i>United European Gastroenterology Journal</i> , 2020, 8, 418-424.	1.6	24
106	Hematologic Indices as Surrogate Markers for Monitoring Thiopurine Therapy in IBD. <i>Digestive Diseases and Sciences</i> , 2015, 60, 478-484.	1.1	23
107	Cytomegalovirus Infection in Pediatric Severe Ulcerative Colitis: A Multicenter Study from the Pediatric Inflammatory Bowel Disease Porto Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 197-201.	1.1	23
108	Ustekinumab in Crohn's disease: evidence to date and place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 208-214.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Deep learning for noninvasive liver fibrosis classification: A systematic review. <i>Liver International</i> , 2021, 41, 2269-2278.	1.9	22
110	The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1924-1929.	0.9	21
111	Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a retrospective analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988159.	1.4	21
112	Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy. <i>Clinical Radiology</i> , 2017, 72, 798.e7-798.e13.	0.5	20
113	Significance of low level infliximab in the absence of anti-infliximab antibodies. <i>World Journal of Gastroenterology</i> , 2015, 21, 1907.	1.4	19
114	Low psoas muscle area is associated with postoperative complications in Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2021, 36, 543-550.	1.0	19
115	Thiopurine Metabolite Ratios for Monitoring Therapy in Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 59, 511-515.	0.9	17
116	Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2013, 4, 18.	0.5	17
117	Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure. <i>Medicine (United States)</i> , 2015, 94, e673.	0.4	16
118	Genetic Predictors of Benign Course of Ulcerative Colitis: A North American Inflammatory Bowel Disease Genetics Consortium Study. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2311-2316.	0.9	16
119	Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1302-1310.	1.1	16
120	Dose optimisation for Loss of Response to Vedolizumab: Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1707-1719.	0.6	16
121	ECCO Topical Review: Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1605-1620.	0.6	16
122	Structural bowel damage in quiescent Crohn's disease. <i>Digestive and Liver Disease</i> , 2017, 49, 490-494.	0.4	15
123	Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohn's disease. <i>Abdominal Radiology</i> , 2018, 43, 3207-3212.	1.0	15
124	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2216.	1.0	15
125	Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease. <i>BMC Gastroenterology</i> , 2017, 17, 27.	0.8	14
126	Bowel preparation in "real-life" small bowel capsule endoscopy: a two-center experience. <i>Annals of Gastroenterology</i> , 2016, 29, 196-200.	0.4	14

#	ARTICLE	IF	CITATIONS
127	Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1655-1661.	0.9	13
128	Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 313-320.	0.6	13
129	Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1117-1125.	1.9	13
130	Monitoring of small bowel Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1047-1058.	1.4	12
131	Impaired IL-10 Receptor-mediated Suppression in Monocyte From Patients With Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 779-784.	0.9	12
132	Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1619-1625.	0.9	12
133	Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. <i>Digestive and Liver Disease</i> , 2022, 54, 192-197.	0.4	12
134	Clinical and radiographic presentation of superior mesenteric vein thrombosis in Crohn's disease: A single center experience. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 543-549.	0.6	11
135	The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn's disease in patients with negative ileocolonoscopy. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481876590.	1.4	11
136	Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1564-1572.e5.	2.4	11
137	Postoperative complications and waiting time for surgical intervention after radiologically guided drainage of intra-abdominal abscess in patients with Crohn's disease. <i>BJS Open</i> , 2021, 5, .	0.7	11
138	Soluble Syndecan-1: A Novel Biomarker of Small Bowel Mucosal Damage in Children with Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 755-760.	1.1	10
139	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. <i>Digestive and Liver Disease</i> , 2019, 51, 1106-1111.	0.4	10
140	A Convolutional Neural Network Deep Learning Model Trained on CD Ulcers Images Accurately Identifies NSAID Ulcers. <i>Frontiers in Medicine</i> , 2021, 8, 656493.	1.2	10
141	Idiopathic liver function test abnormality in pregnancy is associated with assisted reproduction techniques. <i>Fertility and Sterility</i> , 2013, 99, 377-381.e3.	0.5	9
142	Risk of Infections with Biological Agents. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 509-524.	1.0	9
143	Pitfalls in diagnosing colon cancer on abdominal CT. <i>Clinical Radiology</i> , 2017, 72, 858-863.	0.5	9
144	Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients. <i>Gastroenterology</i> , 2013, 144, S-778.	0.6	8

#	ARTICLE	IF	CITATIONS
145	Diagnostic modalities for the evaluation of small bowel disorders. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 111-117.	1.0	8
146	Chromoendoscopy or white light endoscopy for neoplasia detection in Lynch syndrome, a meta-analysis. <i>Digestive and Liver Disease</i> , 2019, 51, 1515-1521.	0.4	8
147	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1062-1066.	0.8	8
148	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1330-1339.	0.9	8
149	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
150	Head or Tail: The Orientation of the Small Bowel Capsule Endoscope Movement in the Small Bowel. <i>Digestive Diseases and Sciences</i> , 2012, 57, 694-698.	1.1	7
151	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 802-806.	0.8	7
152	Assessment of patency capsule retention using MR diffusion-weighted imaging. <i>European Radiology</i> , 2017, 27, 4979-4985.	2.3	7
153	Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1410-1417.	0.6	7
154	Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 167-174.	1.6	7
155	Coexistence of Takayasu's Arteritis in Patients with Inflammatory Bowel Diseases. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-5.	0.7	7
156	Capsule Endoscopy and Deep Enteroscopy in Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2016, 26, 611-627.	0.6	6
157	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 256-257.	0.6	6
158	Fecal occult blood testing for the prediction of small-bowel pathology detected by capsule endoscopy: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2017, 30, 186-191.	0.4	6
159	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 91-97.	0.6	6
160	Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. <i>Gut</i> , 2022, 71, 1988-1997.	6.1	6
161	A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1511-1522.	0.6	6
162	Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease—Are We There Yet?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2753.	1.0	5

#	ARTICLE	IF	CITATIONS
163	Infliximab levels and antibodies in IBD-related peripheral arthralgia. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1141-1148.	1.0	5
164	Evolution of Inflammatory Bowel Disease Research From a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 434-439.	0.9	5
165	Familial ulcerative colitis in Israeli Jews: its prevalence and clinical severity compared to sporadic disease. <i>Annals of Gastroenterology</i> , 2011, 24, 285-289.	0.4	5
166	Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110686.	1.4	5
167	Keeping it simple: mental health assessment in the Gastroenterology Department " using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482110664.	1.4	5
168	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	0.6	5
169	The Lemann Index "A Glance Through the Window of Opportunity?. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw195.	0.6	4
170	Evolution of colorectal cancer screening research in the past 25 years: text-mining analysis of publication trends and topics. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094115.	1.4	4
171	DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S092-S094.	0.6	4
172	Duration of combination therapy and risk of treatment failure in patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101503.	0.7	4
173	P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S412-S414.	0.6	4
174	Retention rate in small-bowel capsule endoscopy. <i>Gastrointestinal Endoscopy</i> , 2017, 86, 573.	0.5	3
175	P392 Comprehensive video capsule endoscopy-based monitoring predicts short and long-term risk of disease flares in small bowel Crohn's disease: A prospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S302-S303.	0.6	3
176	Sa1028 TERMINOLOGY AND DESCRIPTION OF VASCULAR LESIONS IN SMALL BOWEL CAPSULE ENDOSCOPY: AN INTERNATIONAL DELPHI CONSENSUS STATEMENT. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB149-AB150.	0.5	3
177	P571 Effectiveness and safety of Ustekinumab for induction of remission in patients with Crohn's disease: a multi-centre Israeli study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S399-S400.	0.6	3
178	638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, S373-S373.	0.2	3
179	P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S226-S227.	0.6	3
180	Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4265.	1.0	3

#	ARTICLE	IF	CITATIONS
181	P285 Deep learning for automated detection of mucosal inflammation by capsule endoscopy in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S242-S242.	0.6	2
182	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 624-629.	0.6	2
183	Prediction of Recurrent Emergency Department Visits among Patients with Crohn's Disease: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3651.	1.0	2
184	P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S381-S382.	0.6	2
185	Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	2
186	OPO1 Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S001-S001.	0.6	2
187	Artificial Intelligence for the Evaluation of Mucosal Healing in IBD: The Future is Here. <i>Gastroenterology</i> , 2021, 161, 1073-1074.	0.6	2
188	Qualitative sonographic assessment of transmural ileal inflammation in Crohn's disease: a comparison with MRI activity score. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 961-966.	0.8	2
189	Machine learning for prediction of intra-abdominal abscesses in patients with Crohn's disease visiting the emergency department. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110531.	1.4	2
190	P384 Postoperative Endoscopic Recurrence In Patients With Crohn's Disease After Curative Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i384-i385.	0.6	2
191	Cardiovascular Risk Factors and Physical Fitness Among Subjects with Asymptomatic Colonic Diverticulosis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 902-912.	1.1	2
192	Nomenclature and Definition of Atrophic Lesions in Small Bowel Capsule Endoscopy: A Delphi Consensus Statement of the International CAPSULE endoscopy REsearch (I-CARE) Group. <i>Diagnostics</i> , 2022, 12, 1704.	1.3	2
193	795 Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study. <i>American Journal of Gastroenterology</i> , 2019, 114, S460-S460.	0.2	1
194	P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn's disease patients treated with vedolizumab: Results from the EVOLVE study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S360-S361.	0.6	1
195	Predictors of mortality in inflammatory bowel disease patients treated for pneumonia. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093945.	1.4	1
196	Long-term outcome of ulcerative proctitis. <i>United European Gastroenterology Journal</i> , 2020, 8, 847-848.	1.6	1
197	DOP74 Effectiveness of dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S111-S112.	0.6	1
198	Editorial: is vedolizumab effective for perianal Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 912-913.	1.9	1

#	ARTICLE	IF	CITATIONS
199	DOP79 Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S111-S111.	0.6	1
200	Venous Thromboembolism Among Patients With Inflammatory Bowel Diseases is Not Related to Increased Thrombophilia. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	1
201	Fucosyltransferase 2 Mutations Are Associated With a Favorable Clinical Course in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, e166-e170.	1.1	1
202	Postoperative outcomes following inguinal hernia repair in inflammatory bowel disease patients compared to matched controls. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 522-526.	0.8	1
203	P381 Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i382-i382.	0.6	1
204	COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. <i>Vaccines</i> , 2022, 10, 376.	2.1	1
205	Adverse Clinical Outcomes among Inflammatory Bowel Disease Patients Treated for Urinary Tract Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 1359.	1.0	1
206	PTH-077 Fertility and pregnancy related misconceptions in female patients with inflammatory bowel disease. <i>Gut</i> , 2015, 64, A440.1-A440.	6.1	0
207	PTH-078 Pregnancy outcomes in female patients with inflammatory bowel disease. <i>Gut</i> , 2015, 64, A440.2-A441.	6.1	0
208	PTU-072 Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016, 65, A88-A89.	6.1	0
209	PTU-012 Faecal Calprotectin as Predictor of Small-Bowel Crohn's Disease in Capsule Endoscopy – A Systematic Review and Meta-Analysis. <i>Gut</i> , 2016, 65, A57.2-A58.	6.1	0
210	P494 Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S330-S330.	0.6	0
211	AODWE-008 Multicentre ecco collaborative group study to evaluate the need for re-intervention following multimodal treatment in crohn's disease with perianal fistula. , 2017, , .		0
212	PWE-033 Presentation and surgical interventions for crohn's disease with perianal fistula in the biologics era: results from a multicentre study. , 2017, , .		0
213	P211 Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicentre fistula cohorts. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S183-S184.	0.6	0
214	P779 CD patients in deep remission harbor a high dysbiosis index similar to active CD at diagnosis, yet both are higher in comparison to healthy controls. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S479-S479.	0.6	0
215	P189 Diffusion-weighted magnetic resonance enterography for prediction of response to tumour necrosis factor inhibitors in stricturing Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S194-S194.	0.6	0
216	Sa1708 - The Effect of IBD Biologic Drugs on Lymphomatous Transformation of EBV-Infected Peripheral Blood Mononuclear Cells. <i>Gastroenterology</i> , 2018, 154, S-364.	0.6	0

#	ARTICLE	IF	CITATIONS
217	P755 Safety, efficacy, and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-TNF. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S492-S493.	0.6	0
218	347 - Impact of Drug Levels, Anti-Drug Antibodies and $\pm 4^{27}$ Target Occupancy on the Response to Vedolizumab Therapy in Patients with Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, S-84-S-85.	0.6	0
219	Mo1887 - Safety, Efficacy and Pharmacokinetics of Vedolizumab in Patients with Simultaneous Exposure to an Anti-TNF. <i>Gastroenterology</i> , 2018, 154, S-839-S-840.	0.6	0
220	Su1178 - Serum MMP-9 - A Novel Biomarker for Prediction of Clinical Relapse in Patients with Quiescent small Bowel Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, S-495.	0.6	0
221	599 - Comprehensive Video Capsule Endoscopy-Based Monitoring Predicts Short and Long-Term Risk of Disease Flares in Small Bowel Crohn's Disease: A Prospective Cohort Study. <i>Gastroenterology</i> , 2018, 154, S-127.	0.6	0
222	P669 Transmural healing is associated with higher infliximab trough levels in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S454-S454.	0.6	0
223	1150 " Intra-Personal Gut Microbial Variations in Patients with Quiescent Crohn Disease Predict Subsequent Disease Flare. <i>Gastroenterology</i> , 2019, 156, S-246.	0.6	0
224	DOP36 Gut microbial variations in patients with quiescent Crohn's disease predict subsequent disease flare. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S046-S047.	0.6	0
225	48 SMALL INTESTINAL MUCOSAL HEALING ASSESSED BY VIDEO CAPSULE ENDOSCOPY IN CROHN'S DISEASE PATIENTS TREATED WITH ADALIMUMAB: THE SIMCHA STUDY - INTERIM RESULTS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB48.	0.5	0
226	P177 Small intestinal mucosal healing assessed by video capsule endoscopy in Crohn's disease patient treated with adalimumab: The SIMCHA study's interim results. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S177-S178.	0.6	0
227	P565 Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels?. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S396-S397.	0.6	0
228	P221 Thromboembolic events in hospitalised patients with inflammatory bowel disease " a large tertiary hospital experience. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S253-S253.	0.6	0
229	P643 Development of quantitative ultrasonographic activity score in ileal Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S532-S533.	0.6	0
230	P160 A novel PillCam Crohn's capsule score (Eliakim score) for quantification of mucosal inflammation in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S218-S219.	0.6	0
231	P402 Prediction of emergency department re-visit among Crohn's disease patients: a retrospective study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S372-S372.	0.6	0
232	P724 Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S583-S583.	0.6	0
233	P775 Evolution of inflammatory bowel disease research from a bird's eye perspective: A text-mining analysis of publication trends and topics. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S615-S615.	0.6	0
234	P785 Predictors of mortality in IBD patients treated for pneumonia. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S620-S621.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Letter: ustekinumab dose intensification for loss of response“should we re“induce before shortening the dose interval? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 565-566.	1.9	0
236	Mo1811 REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NA“VE NONCOMPLICATED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE EVOLVE STUDY. <i>Gastroenterology</i> , 2020, 158, S-932-S-933.	0.6	0
237	Sa1741 A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE. <i>Gastroenterology</i> , 2020, 158, S-405.	0.6	0
238	Letter: optimising response to ustekinumab therapy for patients with Crohn“™s disease“™ author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 907-907.	1.9	0
239	Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY. <i>Gastroenterology</i> , 2020, 158, S-407.	0.6	0
240	P012 Î±4Î²7 Receptor occupancy by vedolizumab at trough time-point occurs at the membranal level and is not associated with endoscopic healing in inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S135-S136.	0.6	0
241	DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case“™control study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S095-S097.	0.6	0
242	P522 Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S498-S499.	0.6	0
243	P014 Untargeted serum metabolome in longitudinal Crohn“™s Disease (CD) cohort enrolled during remission shows strong individualized signature and CD-associated signals that are maintained also in patients who normalized their fecal calprotectin. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S135-S135.	0.6	0
244	P122 Machine learning for prediction of intra-abdominal abscesses in patients with Crohn“™s disease visiting the emergency department. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S214-S214.	0.6	0
245	P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S307-S308.	0.6	0
246	P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S215-S216.	0.6	0
247	Genetic testing for assessment of lynch syndrome in young patients with polyps. <i>Digestive and Liver Disease</i> , 2021, 53, 1640-1646.	0.4	0
248	D“™finition et description des l“™sions vasculaires de l'intestin gr“™le en vid“™o capsule endoscopique: Consensus international selon la m“™thodologie Delphi. <i>Endoscopy</i> , 2018, 50, .	1.0	0
249	672“™fDefining Meaningful Attributes for the Treatment of IBD From Patients' Perspective. <i>American Journal of Gastroenterology</i> , 2019, 114, S395-S395.	0.2	0
250	Sa1867 LOWER VEDOLIZUMAB TROUGH LEVELS BEFORE INTERVAL SHORTENING ARE NOT PREDICTIVE OF SUCCESS OF THE INTERVENTION. <i>Gastroenterology</i> , 2020, 158, S-457.	0.6	0
251	P192 First event of acute intestinal inflammation and the risk of progression to Inflammatory bowel disease: a retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i254-i255.	0.6	0
252	P344 What our patients are looking for - the common fields of interest in IBD patients: A Google Trends Analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i359-i359.	0.6	0

#	ARTICLE	IF	CITATIONS
253	P676 Burden of depression and anxiety among inflammatory bowel disease patients in a national cohort in Israel – Data from the EPI-IIRN. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i580-i581.	0.6	0
254	P209 Disproportionate low albumin and high neutrophil-to-lymphocyte ratio in small bowel adenocarcinoma in long-term Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i267-i267.	0.6	0
255	P048 Bridging the Gap Between Body and Soul: A Pilot Study Examining Inflammation and Depression / Anxiety in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i162-i162.	0.6	0
256	P583 Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i522-i523.	0.6	0
257	P623 The effectiveness and tolerability of Crohn's disease exclusion diet in adult Crohn's disease patients: a retrospective study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i547-i548.	0.6	0
258	P647 Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i561-i561.	0.6	0
259	P484 Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i451-i451.	0.6	0
260	Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210833.	1.4	0
261	Risk factors and prediction algorithm for advanced neoplasia on screening colonoscopy for average-risk individuals. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211012.	1.4	0
262	Ustekinumab in ulcerative colitis – insights from the real-world data. <i>United European Gastroenterology Journal</i> , 2022, 10, 621-622.	1.6	0